Evommune Shares Slip After 70% Rally Following 33% Eczema Trial Gain
Evommune shares fell after profit-taking following a 70% gain driven by positive Phase 2a results for EVO301 in moderate-to-severe atopic dermatitis. The trial showed a 33% placebo-adjusted Eczema Area and Severity Index improvement at week 12 and 23% of patients achieved near-clear skin, prompting a Phase 2b subcutaneous dose-ranging study.
1. Stock Cools Off After 70% Rally
Evommune shares retreated Thursday after surging about 70% the previous session on profit-taking. The stock is trading roughly 5% below its 20-day and 3% below its 50-day simple moving averages, reflecting short-term weakness despite the recent spike.
2. Phase 2a Results and Next Steps
The Phase 2a proof-of-concept trial for EVO301 in moderate-to-severe atopic dermatitis delivered a 33% placebo-adjusted improvement in the Eczema Area and Severity Index at week 12, with 23% of patients reaching an Investigator’s Global Assessment score of 0 or 1. Evommune plans to launch a Phase 2b dose-ranging study using a subcutaneous formulation and is exploring additional indications, including ulcerative colitis.
3. Analyst Uplift and Sales Forecast
Analysts have raised the probability of success for EVO301 to 51% from 29% and boosted the 2035 sales estimate to $1 billion from $760 million. Upgrades and new target prices from multiple firms underscore growing expectations that EVO301 could achieve blockbuster status in the large atopic dermatitis market and beyond.